Search Results

These 27 markets, comprising countries across Asia, Europe and South America, together contributed some 12% of Lundbeck’s earnings in 2024.

This webinar highlights practical strategies to overcome two key challenges in TCR discovery: poor expression and low affinity. Discover how the innovative WuXian Transient™ system enables high-titer CHO production of sTCRs (~100 mg/L) and TCR-TCEs, and how optimized phage-based affinity maturation routinely delivers ~10,000-fold KD improvements. Through real-world case studies, see how these integrated solutions generate high-quality TCR building blocks in a high-throughput manner, streamlining the path to next-gen TCR-TCE therapeutics.

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Cullinan Therapeutics and Taiho Oncology’s zipalertinib elicited promising response rates in two mid-stage studies of non-small cell lung cancer patients with typical and uncommon EGFR mutations.

Former CDC director Susan Monarez and former chief medical officer Debra Houry will appear in front of the Senate HELP Committee on Sept. 17.